Two Serum Free Light Chain Detection Systems in the Diagnosis of Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2021.04.029
- Author:
Guo-Qing ZHU
1
;
Xue FU
1
;
Yan-Song REN
1
;
Yan-Sheng WANG
1
;
Shou-Lei WANG
1
;
Li-Cheng WANG
1
;
Jun LIN
1
;
Gang AN
2
Author Information
1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020,China.
2. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020,China E-mail: angang@ihcams.ac.cn.
- Publication Type:Journal Article
- MeSH:
Humans;
Immunoglobulin Light Chains;
Immunoglobulin kappa-Chains;
Immunoglobulin lambda-Chains;
Latex;
Multiple Myeloma/diagnosis*
- From:
Journal of Experimental Hematology
2021;29(4):1209-1215
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the comparability of the Freelite, Binding Site, Beckman and N Latex FLC, Siemens in the detection of serum free light chain (sFLC) .
METHODS:Fifty newly diagnosed multiple myeloma (MM) patients in Tianjin Institute of Blood Research from November 2019 to February 2020 were enrolled. The two systems (Freelite, Binding Site, Beckman and N Latex FLC, Siemens) were used to detect the sFLC of the samples. Outlier detection was performed by ESD method, methodological comparison and deviation assessment were performed by Passing-Bablok regression and Bland-Altman regression.
RESULTS:Both the systems could quantitatively analyze free kappa light chain serum samples and free lambda light chain samples. Freelite, Binding Site, Beckman and N Latex FLC, Siemens free light chain test showed FLC-κ：36.5 (6.5, 194), 40.5 (6.94, 288), FLC-λ: 30.1 (4.3, 170.5), 35.1 (2.28, 526), rFLC (FLC-κ/ FLC-λ) : 0.82 (0.05, 43.25), 1.03 (0.03, 32.04), dFLC (｜FLC-κ- FLC-λ｜) : -5.8 (-161.97, 183.7), 1.1 (-505.1, 279.01), which existed no outliers. There were systematic differences, and the deviation level was not within the clinically acceptable range.
CONCLUSION:Both the systems can meet the needs of clinical diagnosis and treatment, but there is a significant deviation between the two systems, the results are not comparable, and should be analyzed separately. In particular, the same system should be selected for monitoring the prognosis of MM.
